$0.40
2.30%
Nasdaq, Fri, Sep 06 2024
ISIN
US05502L1052
Symbol
AZRX
Sector
Industry

AzurRx BioPharma, Inc. Stock price

$0.40
-0.23 36.80% 1M
-7.06 94.70% 6M
-3.81 90.60% YTD
-8.20 95.40% 1Y
-26,311.49 100.00% 3Y
-41,957.65 100.00% 5Y
-208,950.65 100.00% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.01 2.30%
ISIN
US05502L1052
Symbol
AZRX
Sector
Industry

Key metrics

Market capitalization $1.29m
Enterprise Value $66.52m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.05
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-20.93m
Free Cash Flow (TTM) Free Cash Flow $-13.28m
Cash position $3.43m
EPS (TTM) EPS $-49.23
P/E forward 0.00
Short interest 0.17%
Show more

Is AzurRx BioPharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

AzurRx BioPharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast AzurRx BioPharma, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast AzurRx BioPharma, Inc.:

Buy
100%

Financial data from AzurRx BioPharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '24
+/-
%
- -
-
100%
- Direct Costs 0.07 0.07
30% 30%
-
-0.07 -0.07
30% 30%
-
- Selling and Administrative Expenses 17 17
64% 64%
-
- Research and Development Expense 4.24 4.24
245% 245%
-
-21 -21
187% 187%
-
- Depreciation and Amortization 0.07 0.07
30% 30%
-
EBIT (Operating Income) EBIT -21 -21
184% 184%
-
Net Profit -6.16 -6.16
32% 32%
-

In millions USD.

Don't miss a Thing! We will send you all news about AzurRx BioPharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It focuses on MS1819-SD, and B-Lactamase program products. The company was founded on January 30, 2014 and is headquartered in Brooklyn, NY.

Head office United States
CEO James Sapirstein
Employees 9
Founded 2014
Website enterothera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today